Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growt...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julia Niemann, Norman Woller, Jennifer Brooks, Bettina Fleischmann-Mundt, Nikolas T. Martin, Arnold Kloos, Sarah Knocke, Amanda M. Ernst, Michael P. Manns, Stefan Kubicka, Thomas C. Wirth, Rita Gerardy-Schahn, Florian Kühnel
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Q
Acceso en línea:https://doaj.org/article/5216df34738f45e49e9168b8b9041417
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growth inhibition and enhances the therapeutic efficacy of viral oncolysis.